胰高血糖素样受体激动剂与新一代肠促胰素药物:代谢、心血管与肾脏获益
GLP-1受体激动剂最初用于治疗2型糖尿病,降糖高效且低血糖风险低,兼具减重作用。此类药物降低主要不良心血管事件(如非致死性心肌梗死、卒中和心血管死亡)风险及心衰住院或院内治疗风险,减少白蛋白尿并延缓估算肾小球滤过率下降,从而延迟或预防肾衰竭。利拉鲁肽、司美格鲁肽及GIP/GLP-1双受体激动剂替尔泊肽已获批治疗肥胖,临床试验证实对多种肥胖相关疾病有益。当前在探索神经退行性疾病和物质使用障碍等新适应证,并开发口服小分子GLP-1受体激动剂。
要点
- GLP-1受体激动剂降低主要不良心血管事件风险(如非致死性心肌梗死、卒中和心血管死亡),并降低心衰住院或院内治疗风险。
- GLP-1受体激动剂减少白蛋白尿并延缓估算肾小球滤过率下降,从而延迟或预防肾衰竭。
- 利拉鲁肽、司美格鲁肽及替尔泊肽已获批治疗肥胖,临床试验证实可预防2型糖尿病、降低主要不良心血管事件风险、改善射血分数保留的心衰、促进脂肪性肝病脂肪变性消退并预防纤维化、改善阻塞性睡眠呼吸暂停和膝骨关节炎症状。
- 双受体(GLP-1-胰高血糖素和GLP-1-胰淀素)及三受体(GIP-GLP-1-胰高血糖素)激动剂承诺比单受体激动剂更有效,尤其对减重。
- 部分临床开发项目胃肠道不良事件负担高,应优化剂量递增方案以达到可接受的耐受性。
适用人群与场景
- 2型糖尿病患者,用于血糖控制并降低主要不良心血管事件、心衰住院和肾脏进展风险。
- 肥胖患者,使用利拉鲁肽、司美格鲁肽或替尔泊肽治疗肥胖及其相关疾病。
研究设计与关键结果
- GLP-1受体激动剂最初为治疗2型糖尿病而开发,对血糖控制高效,兼具体重减轻益处且低血糖风险低。
- GLP-1受体激动剂降低主要不良心血管事件风险(如非致死性心肌梗死、卒中和心血管死亡),并降低心衰住院或院内治疗风险。
- GLP-1受体激动剂减少白蛋白尿并延缓估算肾小球滤过率随时间下降,从而延迟或预防肾衰竭。
- 利拉鲁肽、司美格鲁肽及GIP/GLP-1双受体激动剂替尔泊肽已获批治疗肥胖,临床试验证实对多种肥胖相关疾病有益:预防2型糖尿病;主要不良心血管事件风险;心衰,尤其是射血分数保留的心衰;脂肪性肝病脂肪变性消退和纤维化预防;阻塞性睡眠呼吸暂停和膝骨关节炎症状改善。
- 当前发展包括探索新适应证(如神经退行性疾病和物质使用障碍),有提示性疗效证据,以及开发口服小分子GLP-1受体激动剂以提高便利性。
- 双受体(GLP-1-胰高血糖素和GLP-1-胰淀素)及三受体(GIP-GLP-1-胰高血糖素)激动剂激活多个受体,承诺比单受体激动剂更有效,尤其对减重。
- 部分临床开发项目胃肠道不良事件负担高,应优化剂量递增方案以达到可接受的耐受性。
证据类型、等级与局限
- 综述
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure. These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure. Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis. Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience. Dual (ie, GLP-1-glucagon and GLP-1-amylin) and triple (ie, GIP-GLP-1-glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss. However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability.
参考来源
- Nauck MA, Tuttle KR, Tschöp MH, et al. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026. PMID: 41547366. doi:10.1016/S0140-6736(25)02105-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。